|
EP2591799A1
|
|
Cancer peptide vaccine
|
|
WO2010050181A1
|
|
Vaccine for preventing onset and recurrence of liver cancer induced by hepatitis c virus
|
|
JP2007291112A
|
|
Tumor antigen
|
|
US2010292138A1
|
|
Peptide Derived from Hepatitis C Virus
|
|
WO2007083763A1
|
|
Method for production of emulsion preparation comprising physiologically active peptide, and kit for production of the preparation
|
|
JP2008107154A
|
|
Method for diagnosing allergy to cedar pollen
|
|
EP1908826A1
|
|
Prostate cancer related protein derived peptide which is a peptide vaccine candidate for prostate cancer patients with hla-a3 supertype alleles
|
|
JP2007322211A
|
|
Method for predicting prognosis of cancer patient
|
|
WO2006080340A1
|
|
Concomitant use of hepatitis c virus-origin peptide with interferon
|
|
EP1767541A1
|
|
Hla-a24- or hla-a2-binding peptide of parathyroid hormone-related protein
|
|
EP1712620A1
|
|
Peptide originating in epidermal growth factor receptor (egfr)
|
|
US2008063643A1
|
|
Peptide Derived From Hepatitis C Virus
|
|
CA2534461A1
|
|
An agent for preventing and/or treating hematologic malignancies
|
|
JP2007145715A
|
|
Hla-a24- or hla-a2-binding peptide of parathyroid hormone-related protein
|
|
EP1454914A1
|
|
Tumor antigen
|
|
EP1473564A1
|
|
Method of detecting cellular immunity and application thereof to drugs
|
|
EP1403283A1
|
|
Tumor antigen
|
